Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1960 2
1961 1
1962 2
1965 1
1967 2
1968 1
1969 6
1974 1
1975 7
1976 11
1977 3
1978 4
1979 3
1980 2
1981 9
1982 8
1983 12
1984 13
1985 13
1986 9
1987 11
1988 7
1989 11
1990 17
1991 14
1992 15
1993 15
1994 23
1995 29
1996 21
1997 15
1998 10
1999 19
2000 17
2001 20
2002 21
2003 31
2004 22
2005 24
2006 18
2007 19
2008 28
2009 32
2010 33
2011 35
2012 42
2013 33
2014 44
2015 40
2016 32
2017 43
2018 44
2019 40
2020 44
2021 36
2022 31
2023 39
2024 41
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,044 results

Results by year

Filters applied: . Clear all
Page 1
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. Among authors: izumi h. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Paz-Ares L, et al. Among authors: izumi h. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23. J Clin Oncol. 2023. PMID: 36689692 Free PMC article. Clinical Trial.
Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, Udagawa H, Izumi H, Shibata Y, Tanaka K, Fujii M, Ohashi A, Seki M, Goto K, Tsuchihara K, Suzuki Y, Kobayashi SS. Kashima Y, et al. Among authors: izumi h. Cancer Res. 2021 Sep 15;81(18):4835-4848. doi: 10.1158/0008-5472.CAN-20-2811. Epub 2021 Jul 9. Cancer Res. 2021. PMID: 34247147 Free PMC article.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z, Yue M, Tang S, Wu F, Sun H, Li Y, Zhang Y, Izumi H, Huang H, Wang W, Xue Y, Tong X, Mori S, Taki T, Goto K, Jin Y, Li F, Li FM, Gao Y, Fang Z, Fang Y, Hu L, Yan X, Xu G, Chen H, Kobayashi SS, Ventura A, Wong KK, Zhu X, Chen L, Ren S, Chen LN, Ji H. Qin Z, et al. Among authors: izumi h. J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990 Free PMC article.
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
Sakai T, Matsumoto S, Ueda Y, Shibata Y, Ikeda T, Nakamura A, Kodani M, Ohashi K, Furuya N, Izumi H, Nosaki K, Umemura S, Zenke Y, Udagawa H, Sugiyama E, Yoh K, Goto K. Sakai T, et al. Among authors: izumi h. J Thorac Oncol. 2023 Nov;18(11):1538-1549. doi: 10.1016/j.jtho.2023.07.024. Epub 2023 Aug 4. J Thorac Oncol. 2023. PMID: 37543207 Free article.
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S, Izumi H, Araki M, Liu J, Tanaka Y, Kagawa Y, Sagae Y, Ma B, Isaka Y, Sasakura Y, Kumagai S, Sakae Y, Tanaka K, Shibata Y, Udagawa H, Matsumoto S, Yoh K, Okuno Y, Goto K, Kobayashi SS. Mori S, et al. Among authors: izumi h. Commun Biol. 2024 Apr 4;7(1):412. doi: 10.1038/s42003-024-06116-6. Commun Biol. 2024. PMID: 38575808 Free PMC article.
Transcription factors and drug resistance.
Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y, Yoshida T, Matsuo K, Miyamoto N, Izumi H. Kohno K, et al. Among authors: izumi h. Eur J Cancer. 2005 Nov;41(16):2577-86. doi: 10.1016/j.ejca.2005.08.007. Epub 2005 Oct 4. Eur J Cancer. 2005. PMID: 16209921 Review.
Review of toxicity studies of carbon nanotubes.
Kobayashi N, Izumi H, Morimoto Y. Kobayashi N, et al. Among authors: izumi h. J Occup Health. 2017 Sep 28;59(5):394-407. doi: 10.1539/joh.17-0089-RA. Epub 2017 Aug 8. J Occup Health. 2017. PMID: 28794394 Free PMC article. Review.
NETosis in pulmonary pleomorphic carcinoma.
Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. Oi H, et al. Among authors: izumi h. Cancer Sci. 2024 Nov 18. doi: 10.1111/cas.16332. Online ahead of print. Cancer Sci. 2024. PMID: 39555736 Free article.
1,044 results